FDA's new rare disease framework faces its first big test with Capricor's DMD drug

Capricor Therapeutics is seeking FDA approval for deramiocel, a cell therapy designed to preserve upper limb function in non-ambulatory Duchenne muscular dystrophy patients. In its Phase 3 trial, the drug slowed upper limb decline by 54% compared to placebo, though the statistical analysis plan was revised, sparking debate and scrutiny from FDA reviewers during an advisory committee meeting.

The debate underscores the core dilemma of the FDA's new Rare Disease Framework Initiative. In small patient populations with progressive diseases, running large trials is nearly impossible, and missing data is common. Experts argue that the FDA needs to explicitly define how it handles analysis plan changes, evaluates the totality of evidence, and values slowing functional loss as a meaningful clinical outcome.

The upcoming decision will reveal whether the FDA's new framework leads to a genuinely flexible approach or simply changes public relations rhetoric. For patients, delaying approval for another multi-year trial means losing irreversible physical independence.